. H89 did not prevent this, suggesting that the dephosphorylation is independent of PKA. 24 hour, but not 15 minute, incubation with the AMPK activator, AICAR, also blocked [Arg Introduction [Arg 8 ]-vasopressin binding to the V2 receptor on the basolateral membrane of principal cells results in production of cAMP and concomitant activation of cAMPdependent protein kinase A (PKA). This enzyme plays multiple roles in the cell, one of which is the regulation of ion transport processes, including Cl -and Na + transport via the cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial Na + channel (ENaC), 488 respectively [1, 2] . The activities of the aforementioned ion channels in various epithelial cell models (human colonic adenocarcinoma T84 cells, mouse principal kidney cortical collecting duct clone 4 cells, and human lung adenocarcinoma H441 cells) have also been shown to be negatively regulated by AMP-activated protein kinase (AMPK) [3] [4] [5] [6] [7] [8] . Moreover, AMPK has been reported to regulate transporters other than CFTR and ENaC, including the Na [8, 9] . AMPK has therefore been described as a cellular energy-ion transport coupling kinase [10] .
AMPK is a serine/threonine (ser/thr) protein kinase composed of a catalytic (α) and regulatory subunits (β & γ), each of which are expressed as multiple isoforms [11] . The activity of this enzyme can be regulated by changes in cellular adenosine monophosphate/adenosine triphosphate (AMP/ATP) ratios during periods of cellular stress. The binding of AMP to the catalytic subunit of AMPK causes an allosteric change allowing the enzyme to be more easily phosphorylated and activated by upstream AMPK kinases (AMPKKs). Known AMPKKs include LKB1, the calcium/calmodulin-dependent protein kinase kinases α and β (CaMMKα & CaMMKβ) and transforming growth factor-β-activated kinase (TAK1) [11] . Each AMPKK can phosphorylate the thr 172 position of the AMPKα subunit. Thr 172 has been the most intensively studied phosphorylation site on AMPK and is considered to be important in determining the degree of enzyme activation.
The Madin-Darby Canine Kidney-Clone 7 (MDCK-C7) cell line is a continuous cell line derived from dog principal cells. These epithelial cells, in contrast to MDCK-C11 cells, have retained multiple characteristics of the renal principal cell type, including high transepithelial resistances (≥ 1000 Ω•cm 2 ) and Na + -retaining responses to aldosterone, insulin-like growth factor-1, and [Arg 8 ]-vasopressin [12] [13] [14] . Moreover, MDCK-C7 cells express CFTR, as do in vivo kidney cells [15] [16] [17] [18] [19] flux. However, this effect of AICAR is independent of AMPK activation and is, at least in part, the result of an inhibition of cAMP production in response to [Arg 8 ]-vasopressin. These data highlight the complex interaction between cAMP and AMPK signaling pathways and show that AICAR can elicit AMPK-independent effects on ion transport processes in MDCK-C7 cells.
Materials and Methods

Materials
Madine Darby Canine Kidney, clone-7 (MDCK-C7) cells were a kind gift from Prof. Hans Oberliethner (Meunster, Germany). H89 and AICAR were purchased from Biomol (Plymouth Meeting, PA) and prepared in DMSO. [Arg 8 ]-vasopressin was purchased as a solution and okadaic acid (OA) was prepared in DMSO. Both were from Sigma Aldrich (St. Louis, MO). Amiloride, also from Sigma Aldrich, was prepared in double-distilled water. Nystatin was prepared in DMSO and was from Sigma Aldrich. Primary antibodies (raised in rabbit) directed against αAMPK, phospho-αAMPK thr172 , ACC, and phospho-ACC ser79 were from Cell Signaling (Danvers, MA). The antibodies used for αAMPK and phospho-αAMPK thr172 detection recognize both α1 and α2 isoforms of AMPK. The antibodies used for ACC and phospho-ACC ser79 detection recognize both αACC and βACC. The anti-LKB1 antibody was from Abcam (Cambridge, MA). Mouse anti-β-actin antibody was purchased from Novus Biologicals (Littleton, CO). Goat-anti rabbit-HRP and goat anti-mouse-HRP secondary antibodies were purchased from Upstate (Lake Placid, NY). The Direct Cyclic AMP Enzyme Immunoassay Kit was from Assay Designs, Inc. (Ann Arbor, MI).
Cell culture MDCK-C7 cells were cultured at 37°C in a humified incubator gassed with 5% CO 2 . Culture media consisted of DMEM/F12 base media (Invitrogen, Carlsbad, CA) supplemented with 5% fetal bovine serum (ICN Biochemicals Inc., Irvine, CA), 1 mM glutamax ® , 25 U/mL penicillin, 25 mg/mL streptomycin (Invitrogen), and 12 mg/L ciprofloxacin (Mediatech Inc., Herndon, VA). Cells were maintained in plastic culture flasks. For electrophysiological and biochemical analyses, the cells were subcultured onto permeable supports (Costar ® Transwells, Corning, Acton, MA) for at least 14 days. Fresh media was supplied to all cell cultures three times per week.
Electrophysiology
Ussing-style electrophysiology was used to investigate net transepithelial ion flux in the form of short-circuit current (SCC). Cells grown on 0. 4 Immunoblotting MDCK-C7 cells grown on permeable supports were washed twice with cold Hank's Balanced Salt Solution (Mediatech Inc., Herndon, VA). Cell lysis buffer (4% SDS, 10% glycerol in 0.5 M Tris, pH 6.8) was added directly to epithelial cultures and cells were scraped with a rubber policeman. 9 μL protease inhibitor cocktail (Sigma) per mL cell lysis buffer was added to prevent protein degradation. Protein concentrations in samples were determined with the DC protein assay (Biorad, Hercules, CA). 20 μg of protein were separated by SDS-PAGE on 7.5% acrylamide gels and transferred onto PVDF blotting membrane. Membranes were blocked for 1 hr at room temperature in 5% BSA diluted in wash buffer (0.01% Tween-20 in TBS, pH 7.6). All primary antibodies were diluted in 5% BSA diluted in wash buffer. Membranes were incubated with primary antibody overnight at 4°C, and then incubated in 3 changes of wash buffer for 5 min. each. This was followed by 1 hr incubation in secondary antibody, diluted with 5% milk in wash buffer, at room temperature. Three, 5 min. incubations in wash buffer followed. Protein bands were visualized with West Dura Enhanced Chemiluminescent Reagent and developed either on ClearBlue film (Pierce, Rockford, IL) or with a Molecular Imager ChemiDoc XRS System (Biorad). In order to compare relative amounts of pACC ser79 and pAMPK thr172 , as well as ACC and AMPK, PVDF blotting membranes were cut lengthwise after transfer at ~ 75 kDa and 50 kDa. This yielded three pieces of membrane for immunoblotting -one for pACC ser79 or ACC, one for pAMPK thr172 or AMPK, and one for β-actin (loading control).
Nucleotide Extraction and High Performance Liquid Chromatography
Polarized MDCK-C7 cells were washed twice with icecold HBSS on ice. Cells were scraped in 500 μL 0.4 M cold perchloric acid on ice and spun for 3 min. at 9825 x g. A fixed volume of supernatant was removed and neutralized with 3 M K 3 PO 4 and extracts were analyzed with high performance liquid chromatography (HPLC) according to the reverse-phase procedures described previously [20, 21] . The equipment used was the Hewlett-Packard 1100 series linked to a diode array detector. The perchlorate precipitate was re-suspended in 500 μL 0.5 M NaOH and the protein content was determined using a Bradford assay. ]-vasopressin (100mU/mL) for 10 seconds. Each culture was washed twice with 37°C Hank's Balanced Salt Solution and incubated for 10 min. with 1% Triton X-100 in 0.1M HCl at 37°C. Lysates were centrifuged for 1 min. at 14,243 x g to remove cellular debris. Protein concentrations and cAMP concentrations per sample were determined with the RC/DC Protein Assay and the Direct Cyclic AMP Enzyme Immunoassay Kit, respectively. Final cAMP concentrations were calculated as pmol cAMP/mg protein.
Statistics
Differences between two or more groups in a given experiment were analyzed by a one-way ANOVA followed by a Tukey's post-hoc test using SPSS 14.0 statistical software. Student's t-test was used to analyze experiments containing only two groups. Differences were considered significant where p ≤ 0.05. Symbols in line and bar graphs represent means ± SEM. Line and bar graphs were generated using Sigma Plot 2000 graphing software. ]-vasopressin stimulation were significantly blocked by short-term (10 min) and long-term (24 hr) treatment with H89, a PKA inhibitor (Fig. 1A and B respectively), supporting a role for the PKA signaling pathway in mediating these ion transport events. 8 ]-vasopressin on AMPK activity Activation of AMPK has been shown to negatively regulate CFTR and ENaC in multiple epithelial cell models [3] [4] [5] [6] [7] [8] . Therefore, we postulated that changes in [Arg ]-vasopressin (100 mU/ mL) for ~20 seconds prior to lysis. Cells were solubilized and proteins were separated by SDS-PAGE and transferred to PVDF in preparation for immunoblotting. PVDFs were cut into thirds and probed for pACC ]-vasopressin stimulated ion transport we used AICAR, an AMP analogue known to result in the activation of AMPK. Fig. 3A shows that short-term (15 min) incubation with (Fig. 3B) . We also permeabilized the basolateral membrane with nystatin, thereby eliminating any ion conductances that alter Cl -secretion, and imposed a Cl -gradient across the epithelium. AICAR (24 hrs) significantly inhibited apical Cl -secretion under permeabilized conditions, suggesting that the compound is affecting the activity of Cl -channels located in the apical membrane (Fig. 4) .
Results
Effect of [Arg
Effect of AICAR on AMPK activity
To verify the involvement of AMPK in the observations described in the previous section, cells treated both shortand long-term with AICAR were analyzed for pAMPK ]-vasopressin (100mU/mL) for ~20 seconds prior to lysis. Cells were solubilized and proteins were separated by SDS-PAGE and transferred to PVDF in preparation for immunoblotting. PVDFs were cut into thirds and probed for pACC ]-vasopressin (100 mU/mL) for 20 sec and assayed for cAMP content. Bars represent the means ± SEM for 6 individual experiments. *p ≤ 0.05 by a oneway ANOVA followed by Tukey's post-hoc test. levels. Surprisingly, both short-and long-term challenge with AICAR inhibited cAMP production following [Arg 8 ]-vasopressin stimulation (Fig. 6) . These results are only partially consistent with the ion transport results described ]-vasopressin (100 mU/mL) for ~20 sec. Cells were prepared for nucleotide extraction and HPLC. Nucleotide levels were normalized to the amount of protein in each sample. Bars represent the means ± SEM for 3 individual experiments containing 3 replicates each. *p ≤ 0.05 by a one-way ANOVA followed by Tukey's post-hoc test. ATP, adenosine triphosphate; ADP, adenosine diphosphate; AMP, adenosine monophosphate; NAD, nicotinamide dinucleotide; GTP, guanosine triphosphate; GDP, guanosine diphosphate; TAN, total adenine nucleotide. ]-vasopressin (100 mU/ mL) for ~20 seconds prior to lysis. Cells were solubilized and proteins were separated by SDS-PAGE and transferred to PVDF in preparation for immunoblotting. PVDFs were cut into thirds and probed for pACC in Fig. 3 , where only long-term AICAR treatment, but not short-term, significantly blocked ion transport.
Effect of AICAR and [Arg 8 ]-vasopressin on cellular nucleotides
The cellular nucleotide pool has been demonstrated to change in cells treated with AICAR. We investigated whether such changes may underlie the effects elicited by AICAR. Long-term AICAR treatment caused a significant increase in total adenine nucleotide concentrations, which was not altered after [Arg 8 ]-vasopressin stimulation (Fig. 7) . This can be attributed to an increase in both AMP and ATP; however, no changes in the AMP/ATP ratio were detected. AICAR signifi- ]-vasopressin-induced dephosphorylation of AMPK was not via a decrease in the AMP/ATP ratio, which would result in an allosteric change in AMPK, making this less able to be phosphorylated by AMPKKs.
MDCK-C7 cells do not express LKB1
It was unexpected that AICAR did not increase pAMPKthr172 or cellular nucleotide levels. AICARinduced activation of AMPK is thought to require the upstream kinase, LKB1. Therefore, we hypothesized that this protein may not be expressed in MDCK-C7 cells. Fig. 8 shows that no LKB1 could be detected in the MDCK-C7 cells. Moreover, the Xenopus laevis A6 and mpkCCD cl4 (mouse principal kidney cortical collecting duct clone 4) cell lines, both of which model the principal cell type, showed little to no LKB1 expression. The protein was however, detected in H441 cells, as previously shown [7] . ]-vasopressin had no effect on cellular nucleotide pools, we turned our attention to the role of the ser/thr phosphatases in dephosphorylation of AMPK. There are 2 families-phosphatase 1 (PP1) and phosphatase 2 (PP2)-the latter being composed of 3 subfamilies, 2A, 2B, and 2C. Okadaic acid (OA) is a wellknown phosphatase inhibitor, and can be used at concentrations of up to 1 μM to inhibit PP2A independently from PP1s, PP2B, or PP2C [22] . As expected, acute (30 min.) incubation with OA resulted in substantial increases in both pAMPK thr172 and pACC ser79 abundances (Fig. 9 ). This verifies that PP2A mediates, ]-vasopressin stimulates CFTR and ENaC activity by increasing the production of cAMP, which in turn activates PKA. H89 inhibits PKA activity. In the current studies, AICAR inhibits the production of cAMP. AMPK can be activated by increases in AMP/ATP, followed by phosphorylation by AMPKKs. Conversely, AMPK can be de-activated by dephosphorylation via PP2A. In the current studies, AMPK is not activated by AICAR.
Effect of okadaic acid on [Arg
[ AICAR uptake into the cell occurs via nucleoside transporters, and the compound is then phosphorylated into ZMP by adenosine kinase [24] . ZMP activates AMPK independently of changes in the AMP/ATP ratio.
Previously published literature showed that AICAR inhibits forskolin-stimulated Cl -currents via activation of AMPK [4, 5] . Unexpectedly, we could not detect substantial changes in AMPK activation (as defined by changes in pAMPK thr179 ) after short-or long-term AICAR challenge. These data suggest that in MDCK-C7 cells, AICAR inhibits ion transport via an AMPKindependent mechanism. While this is the first report of such a mechanism in epithelial cells, AICAR-mediated, AMPK-independent apoptosis has been described in Jurkat cells [25] . Furthermore, the biological effects of AICAR in Jurkat cells did not rely on the conversion of the activator into ZMP. In addition, inhibition of adenosine kinase prevented the activation of AMPK in human polarized retinal pigment epithelial cells [26] . Therefore, low adenosine kinase activity in MDCK-C7 cells may account for AICAR being unable to activate AMPK. We found that AICAR caused a significant increase in both ATP and ADP, which is in direct contrast to a recent study performed in H441 cells where AICAR significantly decreased ATP and ADP [8] . AICAR can be further metabolized into ATP, ADP, and AMP in the cell as it is an intermediate of the de novo purine biosynthetic pathway [27] . Thus, our data would support AICAR conversion to ZMP in MDCK-C7 cells. Why then AICAR does not activate AMPK in MDCK-C7 cells is not known; however, AICAR activation of AMPK is thought to require the upstream kinase, LKB1. We could not detect LKB1 in the MDCK-C7 cells nor two other principal cell models, the A6 and mpkCCD cl4 cell lines. The antibody used against LKB1 is reported to cross-react with human, mouse, and rat. Therefore, the antibody may not recognize dog LKB1. This is, however, unlikely, in that no LKB1 was detected in the mouse mpkCCD cl4 (an alternative principal cell line) cells. Thus, it is possible that the absence of LKB1 and/or other upstream kinases prevents AMPK activation by AICAR in the MDCK-C7 cells.
As [Arg 8 ]-vasopressin elevates cAMP to stimulate ion transport, we speculated that 24 hr AICAR challenge may alter cellular cAMP levels. Surprisingly, both shortand long-term AICAR treatment inhibited cAMP production after [Arg 8 ]-vasopressin stimulation. There was a small rise in cAMP in response to [Arg 8 ]-vasopressin with 15 min AICAR treatment. Even though the slight increase in cAMP by [Arg 8 ]-vasopressin was not significantly different from control-treated cells, there may still have been enough cAMP to activate ion transport. Walker et al showed that 48 hour treatment with AICAR lowered forskolin-stimulated Cl -currents in mouse colon and decreased apical CFTR expression in T-84 cellseffects that were shown without demonstrating activation of AMPK [6] . Such an effect of AICAR (to lower apical CFTR expression) is consistent with the permeabilization studies described in Fig. 4 . Therefore, our observation of decreased Cl -current with 24 hr AICAR challenge may be a combined effect of lowered cAMP production and CFTR expression.
Earlier published reports state that PP2A mediates the dephosphorylation of AMPK at thr 172 [22] and that PP2A is activated by cAMP-elevating agents [28, 29] . We confirmed that PP2A dephosphorylates AMPK in MDCK-C7 cells using the phosphatase inhibitor, OA. Moreover, [Arg 8 ]-vasopressin-induced dephosphorylation of AMPK is reversed by OA, indicating that this effect is mediated by PP2A. However, the vasopressin stimulated dephosphorylation of AMPK is independent of cAMP as demonstrated by the results in Figure 6 showing vasopressin-induced dephosphorylation in the presence of AICAR which inhibits cAMP production. Thus, we speculate that [Arg 8 ]-vasopressin may activate PP2A by a mechanism that does not rely on increases in cAMP.
In conclusion, [Arg Fig. 10 . This is the first description in epithelial cells that [Arg 8 ]-vasopressin is a potent regulator of AMPK phosphorylation and that AICAR can modify ion transport independently of AMPK activation. These data show that the signaling pathways regulating ion channel function in epithelial cells are undoubtedly complex and vary considerably between cell types. More work will be required to elucidate the interactions between these pathways. In the interim, in the light of these data, we suggest that biological effects attributed to AICAR (and thus AMPK) must be analyzed with caution.
